Digital Medicine
We work with founders to build companies leveraging AI, machine learning and data analytics to transform healthcare and medicine.
Our approach is evidence-based, rooted in rigorous scientific research and clinical validation and builds on Sofinnova's 50 years of experience in the life sciences sector.
| Close | Fund | AMT |
|---|---|---|
| 2023 | Sofinnova Digital Medicine I | $200 million |
Close: 2023
Fund: Sofinnova Digital Medicine I
AMT: $200 million
"We bring our experience in biological innovation coupled with powerful computing and AI capabilities to build deeply technical companies to product-market fit. This is what makes our approach unique."
"We designed this strategy to help founders leverage our knowledge of a highly-regulated and complex healthcare industry while drawing on the strengths of tech-industry approaches like rapid product iteration and swift commercialization."
The
Team
Companies
Fund iteration
Status
Deal lead
Related News
Signature of a partnership agreement with Kiro
Ex-Google DeepMind and Owkin scientists team up to create Bioptimus to build the first universal AI foundation model for biology
deepc acquires Osimis platform: strengthening the AI infrastructure for radiology at scale
Betteromics raises $20 million in Series A financing, led by Sofinnova Partners and Triatomic Capital
L’école AI, creator of “machine teaching” technology, raises 3 million USD in Seed funding from Sofinnova Partners